Antibiotic Resistance

Overview

Antibiotic resistance evolves when genetic variation allows some microbes to withstand an antimicrobial exposure. Treatment then removes susceptible competitors, increasing the relative success of resistant organisms.

Technical foundations

Resistance phenotypes arise through target modification, enzymatic drug destruction, reduced permeability, active efflux, pathway bypass and biofilm-associated physiology. Genes can move on plasmids, transposons and integrons through conjugation, transformation or transduction. Selection depends on the pharmacokinetic and pharmacodynamic exposure experienced by a microbial population, not simply whether a drug was present. Minimum inhibitory concentration is an operational laboratory threshold; clinical outcome also depends on infection site, host immunity, achievable drug concentration and whether resistance emerges in a subpopulation during therapy.

How it works

Resistance can arise through mutation or horizontal gene transfer. Mechanisms include drug-inactivating enzymes, altered targets, reduced uptake and active efflux. Resistance genes spread through microbial populations and between environments under selective pressure.

Measurement and research methods

Clinical laboratories measure susceptibility by broth microdilution, disk diffusion or gradient methods interpreted against standard breakpoints. Whole-genome sequencing identifies known determinants and supports outbreak reconstruction, but genotype does not always predict expression or phenotype. Surveillance combines isolate data, prescribing information and patient or environmental metadata while correcting for biased sampling. Experimental evolution, competition assays and transcriptomics quantify resistance mechanisms and fitness costs. Rapid diagnostics seek to identify both organism and susceptibility early enough to narrow empiric therapy without delaying treatment for severe infection.

Key ideas

• People do not become resistant; microbial populations do.
• Resistance can spread even when the resistant strain initially grows more slowly.
• Diagnostics, infection prevention and appropriate drug use act on different parts of the problem.

Current research frontier

Research increasingly treats resistance as a One Health systems problem linking hospitals, communities, animals, wastewater and international transmission. New approaches include beta-lactamase inhibitors, bacteriophages, anti-virulence agents, monoclonal antibodies and regimens designed through evolutionary principles. Stewardship aims to optimise agent, dose, route and duration rather than simply minimise all use. Important challenges include financing antibiotics whose use should remain restricted, validating resistance predictions for diverse lineages, and preventing unequal access to diagnostics and effective treatment from undermining population-level control.

Why it matters

Resistance threatens reliable treatment of common infections and complicates surgery, transplantation and cancer care. Surveillance and stewardship help preserve existing drugs while research seeks new therapies and diagnostics.

Limits and open questions

Evolution cannot be eliminated, and reducing one source of antibiotic use is not a complete solution. Human health, animal health, agriculture, sanitation and environmental pathways are interconnected.